View source for NANJING HANXIN PHARMACEUTICAL TECHNOLOGY CO., LTD. (20240343772). Fusion protein and its preparation method for intermediate polypeptide of Semaglutide simplified abstract

=Fusion protein and its preparation method for intermediate polypeptide of Semaglutide=


==Organization Name==

[[:Category:NANJING HANXIN PHARMACEUTICAL TECHNOLOGY CO., LTD.|NANJING HANXIN PHARMACEUTICAL TECHNOLOGY CO., LTD.]]


[[Category:NANJING HANXIN PHARMACEUTICAL TECHNOLOGY CO., LTD.]]

==Inventor(s)==

[[:Category:Jing Wang of Nanjing (CN)|Jing Wang of Nanjing (CN)]][[Category:Jing Wang of Nanjing (CN)]]

[[:Category:Chuangen Tang of Nanjing (CN)|Chuangen Tang of Nanjing (CN)]][[Category:Chuangen Tang of Nanjing (CN)]]

[[:Category:Teng Zhang of Nanjing (CN)|Teng Zhang of Nanjing (CN)]][[Category:Teng Zhang of Nanjing (CN)]]

[[:Category:Xiaoyang Fan of Nanjing (CN)|Xiaoyang Fan of Nanjing (CN)]][[Category:Xiaoyang Fan of Nanjing (CN)]]

[[:Category:Bo Jin of Nanjing (CN)|Bo Jin of Nanjing (CN)]][[Category:Bo Jin of Nanjing (CN)]]

==Fusion protein and its preparation method for intermediate polypeptide of Semaglutide - A simplified explanation of the abstract==


This abstract first appeared for US patent application 20240343772 titled 'Fusion protein and its preparation method for intermediate polypeptide of Semaglutide

The invention pertains to a fusion protein and its preparation method for the intermediate polypeptide of semaglutide, falling within the realm of genetic engineering and polypeptide preparation. The fusion protein consists of a fusion peptide, a protease cleavage site, and a target main molecular sequence. Through optimizing the fusion peptide sequence, modifications in the isoelectric point and hydrophilicity of the protein, the expression of the fusion protein is significantly enhanced to 13.1 g/L. Additionally, the properties of the fusion protein are enhanced, facilitating subsequent extraction, enzyme digestion, and purification processes. The yield of the intermediate polypeptide after enzyme digestion is 3.62 g/L. The production cost of semaglutide intermediate polypeptide Arg34GLP-1(9-37) is reduced, enabling industrial scale-up and suitable for large-scale production.

* Fusion protein optimized for increased expression and improved properties
* Enhanced yield of intermediate polypeptide after enzyme digestion
* Reduced production cost of semaglutide intermediate polypeptide
* Suitable for industrial scale-up and production
* Conducive to subsequent extraction, enzyme digestion, and purification processes

**Potential Applications:**
The technology can be applied in the pharmaceutical industry for the production of semaglutide intermediate polypeptide, specifically targeting the development of diabetes treatments.

**Problems Solved:**
The technology addresses the need for cost-effective and efficient production methods for semaglutide intermediate polypeptide, reducing production costs and enhancing yield.

**Benefits:**
- Increased expression of fusion protein
- Improved properties of the fusion protein
- Cost reduction in the production of semaglutide intermediate polypeptide
- Facilitates industrial scale-up and production

**Commercial Applications:**
The technology can be utilized by pharmaceutical companies for the large-scale production of semaglutide intermediate polypeptide, catering to the demand for diabetes treatment medications in the market.

**Questions about the Technology:**
1. How does the optimization of the fusion peptide sequence contribute to the increased expression of the fusion protein?
2. What are the specific properties of the fusion protein that are enhanced through modifications in the isoelectric point and hydrophilicity?


==Original Abstract Submitted==

the invention discloses a fusion protein and its preparation method for intermediate polypeptide of semaglutide. the invention belongs to the technical field of genetic engineering and polypeptide preparation. the fusion protein comprises a fusion peptide, a protease cleavage site and a target main molecular sequence. by optimizing the fusion peptide sequence, changing the isoelectric point and hydrophilicity of the protein, the highest expression of the fusion protein is effectively increased to 13.1 g/l. meanwhile, the properties of fusion protein are also improved, which is conducive to the development of subsequent extraction, enzyme digestion and purification processes. the yield of intermediate polypeptide after enzyme digestion is 3.62 g/l. the production cost of semaglutide intermediate polypeptide arg34glp-1(9-37) is reduced from the source, which is conducive to industrial scale-up and suitable for industrial production.



[[Category:C07K14/605]]
[[Category:C07K7/06]]
[[Category:C07K14/00]]
[[Category:C12N1/20]]
[[Category:C12P21/02]]
[[Category:C12R1/19]]
[[Category:CPC_C07K14/605]]